An international clinical trial has found that an oral form of semaglutide, a widely used diabetes drug, reduced the risk of serious heart failure events in people with type 2 diabetes who already had heart failure. The findings, published in JAMA Internal Medicine, come from a large randomized trial of nearly 9,650 adults who have both type 2 diabetes and either cardiovascular disease or chronic kidney disease. Researchers followed participants for nearly four years as part of the Semaglutide Cardiovascular Outcomes, or SOUL, Trial. The results are from a secondary analysis of those data.
This article was originally published on MedicalXpress.com
